Dr. Klaus Romero is a clinical pharmacologist and epidemiologist. As an Assistant Professor of Pharmacology at the Colombian Military University and as an Instructor for the American Heart Association’s BLS, ACLS and ACLS-EP courses, Dr. Romero was also a clinical research consultant for Astra-Zeneca Colombia, and worked as a clinical pharmacologist for the CIEO Foundation, a non-profit organization, focused on drug safety research and pharmacovigilance in Colombia. In 2003 he planned, organized and implemented the Colombian National Police Health Services’ Pharmacovigilance system, still operating today. He is a fellow of the American College of Clinical Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has conducted research on endemic channels for non-steroidal anti-inflammatory drug-related gastropathy, antibiotic-related dysglycemia, drug-induced QT prolongation, pharmacoepidemiology and patient education. Dr. Romero has been with C-Path since January of 2008, where he has helped lead clinical pharmacology, pharmacoepidemiology and modeling and simulation projects for the Coalition Against Major Diseases, the Polycystic Kidney Disease Outcomes Consortium and the Critical Path to TB Drug Regimens Consortium, achieving major milestones such as the first regulatory endorsement by FDA and EMA of a clinical trial simulation tool for mild and moderate Alzheimer’s Disease. He is fluid in English, Spanish, German and Portuguese, and has published in the areas of clinical pharmacology, pharmacometrics, cardiovascular drug safety and pharmacoepidemiology.